Amneal Pharmaceuticals (AMRX) Misses Q1 EPS by 4c, Revenues Beat; Affirms FY19 EPS Outlook

Amneal Reports First Quarter 2019 Financial Results

May 9, 2019 6:30 AM EDT

Q1 2019 Net Revenue of $446 Million; GAAP Loss per share of $0.37; Combined Adjusted Diluted EPS(1) of $0.14

Continued Progress in Diversifying Portfolio and Optimizing Business

Reaffirming Full Year 2019 Financial Guidance

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the Company) announced its results today for the first quarter ended March31, 2019.

Summary of GAAP and Non-GAAP Combined and Adjusted Results

(Unaudited; In thousands, except per share amounts)

Three Months Ended

March 31,
2019

March 31,
2018

Year/ Year
Variance

GAAP Results(2) Net revenue $ 446,120 $ 275,189... More